These data, together with the observation that P-selectin was expressed by pneumocytes in a patient who died of severe COVID-19, suggest that a subset of COVID-19 patients may be treated with therapies that inhibit P-selectin [14,36], thus reducing severe acute lung injury, as was demonstrated in a murine model [37]. Here, SELP is linked to COVID-19.